Physician profile
Michael Spivak
NPI 1437499076
$15,707.30
in general payments reported to CMS, 2019-2025
56 companies · $2,753 in 2025
The $2,753 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,628 · 2022: $2,604 · 2023: $3,428 · 2024: $3,295 · 2025: $2,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,446 · Education: $29.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,446.13 |
| Education | $29.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,941.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,783.15 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $956.26 | 2021-2025 | |
| Amgen INC. | $897.92 | 2021-2025 | Repatha, Repatha, Evenity |
| Amarin Pharma, INC. | $807.88 | 2021-2023 | |
| Corcept Therapeutics | $737.23 | 2021-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $735.62 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $625.22 | 2021-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $549.54 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.18 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $417.67 | 2021-2025 | Xifaxan, Cycloset |
| Insulet Corporation | $373.78 | 2022-2025 | Omnipod |
| Beta Bionics, INC. | $365.25 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic, INC. | $357.97 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $280.22 | 2021-2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $275.77 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $275.57 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $264.54 | 2024-2025 | Crysvita |
| Ibsa Pharma INC. | $261.19 | 2021-2024 | Tirosint, Tirosint, Licart |
| Aimmune Therapeutics, INC. | $253.75 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $242.90 | 2021-2024 | Nexletol |
| Alexion Pharmaceuticals, INC. | $212.55 | 2021-2024 | Strensiq |
| Horizon Therapeutics Plc | $207.56 | 2022-2023 | Tepezza |
| Neurocrine Biosciences, INC. | $207.19 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $206.49 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $200.60 | 2023-2025 | Yorvipath |
| Dexcom, INC. | $196.90 | 2024-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $157.96 | 2025 | Isturisa |
| Kowa Pharmaceuticals America, INC. | $143.50 | 2021-2022 | |
| Clarus Therapeutics INC. | $134.19 | 2021 | |
| Nestle Healthcare Nutrition INC. | $105.93 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $97.37 | 2021-2024 | Unithroid |
| Antares Pharma, INC. | $92.95 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Sequel Med Tech, LLC | $89.09 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $74.13 | 2021-2024 | Evkeeza |
| Acella Pharmaceuticals, LLC | $71.31 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $69.98 | 2022-2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $57.73 | 2021-2022 | |
| Amphastar Pharmaceuticals, INC. | $54.52 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $50.68 | 2023-2024 | Voquezna |
| Pfizer INC. | $49.13 | 2021-2023 | |
| Madrigal Pharmaceuticals | $45.05 | 2025 | Rezdiffra |
| Lifescan, INC. | $33.04 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $30.48 | 2021 | |
| Abbott Laboratories | $29.50 | 2021 | |
| Shield Therapeutics INC | $24.05 | 2025 | |
| Merck Sharp & Dohme LLC | $23.55 | 2022 | |
| Alvogen INC | $23.09 | 2025 | Teriparatide |
| Csl Behring | $21.25 | 2024 | Kcentra |
| Phadia US INC. | $20.75 | 2025 | Immunocap |
| Vivus LLC | $19.86 | 2024 | Pancreaze |
| Amryt Pharma Holdings LTD | $18.30 | 2022 | |
| Verity Pharmaceuticals INC. | $15.28 | 2024 | Tlando |
| Radius Health, INC. | $13.96 | 2021 | |
| Zealand Pharma US, INC. | $13.17 | 2021 | |
| Tolmar, INC. | $13.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spivak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.